Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

B cells can both help and hinder the body's defense against melanoma.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

Ritlecitinib works well and is safe for treating alopecia areata.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

Bexarotene gel shows promise as a new treatment for alopecia areata.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

A patient with patchy hair loss was successfully treated for Tumid Lupus Erythematosus after other treatments failed.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Co-trimoxazole may help treat autoimmune diseases.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

The nanocomposite effectively targets lung cancer cells without harming normal cells.

Eclipta alba extract may help fight cancer and has antioxidant benefits without being toxic.

A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.

Montelukast is linked to increased risks of suicidal thoughts and depression.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.